p-cab

P-CAB agent 2 hydrochloride is a potent, orally active potassium-competitive acid blocker (P-CAB) and gastric acid secretion inhibitor. It effectively inhibits H+ K+-ATPase activity, with an IC50 value of <100 nM, and targets the hERG potassium channel with an IC50 value of 18.69 μM. Moreover, P-CAB agent 2 hydrochloride demonstrates no acute toxicity and effectively inhibits histamine-induced gastric acid secretion [1].

P-CAB Agent 2 is a potent, orally active potassium-competitive acid blocker (P-CAB) and gastric acid secretion inhibitor that effectively inhibits H+ K+-ATPase activity, showing an IC50 value of <100 nM. It also demonstrates inhibition of the hERG potassium channel with an IC50 value of 18.69 M, indicating no acute toxicity. P-CAB Agent 2 effectively curbs histamine-induced gastric acid secretion [1].

P-CAB agent 1 (compound B19) is a potassium-competitive acid blocker with an IC50 of 60.50 nM for H+ K+-ATPase, used in the study of acid-related diseases (ARDs).

PF 03716556 (PF-3716556) , an effective and specific P-CAB (potassium-competitive acid blocker), is utilized for the treatment of gastroesophageal reflux disease.

Vonoprazan fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+ K+, ATPase.

Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Revaprazan hydrochloride (YH1885) is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity.

4-CAB hydrochloride is an analog of p-chlorophenylisopropylamine, serving as a psychoactive compound that inhibits the reuptake of serotonin (IC50 = 330 nM) and dopamine (IC50 = 2.3 μM).

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3].

Ar-H047108 free base is an imidazopyridine potassium competitive acid blocker (P-CAB). This drug may be used to treat early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity.

Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis